MINIMUM bio Information

The proteome has no place to hide. MINIMUM Bio is a drug target discovery and molecular glue therapeutics company based in Sydney, Australia, and Austin, Texas. Founded 2022. Mercurious® — our flagship platform — uses phage-displayed cDNA libraries to identify, with no prior assumptions, which proteins in the human proteome bind any given bioactive compound. Built on 25 years of phage display expertise, Mercurious screens the entire expressed proteome simultaneously, reaching low-abundance proteins invisible to mass spectrometry and returning primary target data in 1–2 weeks at a fraction of conventional cost. Works equally on small molecules, biologics, and molecular glues. Our PKS-engineered rapalog library generates structural analogues of rapamycin via a plug-and-play biosynthetic framework. Each rapalog recruits FKBP12 into proximity with a target protein — forming ternary complexes that engage biology inaccessible to conventional small molecules. Three active programmes: validated transcription factor molecular glue in oncology · next-generation immunosuppressants and a best-in-class immunosuppressants · mTORC1-selective rapalogs for healthspan. We partner with pharma and biotech to unblock stalled pipelines, reach undruggable targets, and co-develop FKBP12-recruiting compounds within agreed therapeutic areas. Early partners gain co-invention rights on identified targets. Seeking Seed investment and co-development partnerships. #molecularglues #drugtargetdiscovery #phagediisplay #rapalogs #biotech #longevity #oncology